Garth Lees-Rolfe - Apr 1, 2024 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Chief Financial Officer
Signature
/s/ Garth Lees-Rolfe
Stock symbol
IKT
Transactions as of
Apr 1, 2024
Transactions value $
$0
Form type
4
Date filed
4/2/2024, 05:14 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (right to buy) Award $0 +90K $0.00 90K Apr 1, 2024 Common Stock 90K $2.16 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-third of the options will vest and become exercisable on April 1, 2025, one-third of the options will vest and become exercisable on April 1, 2026, and one-third of the options will vest and become exercisable on April 1, 2027, in each case subject to continued employment through each such vesting date.